×
‘Ghost of Yotei’ Is a Stronger, Self-Assured Sequel

‘Ghost of Yotei’ Is a Stronger, Self-Assured Sequel

There was a moment early on in Ghost of Yotei where I knew it’d won me over. As Atsu, I wasn’t hunting down the Yotei Six who killed my family and left me for dead back in my youth; I was taking on a simple bounty who’d managed to get the better of me. I was all set to watch him plunge his katana in my back and restart the swordfight. Instead, a wolf jumped in out of nowhere, biting him and granting me full health so I could get back up and resume the fight and get my bounty. 

I wouldn’t really see that wolf again until later on when I was led to one of its many dens around the land, but that last-minute save has come to define my experience with Sucker Punch’s first outing exclusive to the PlayStation 5. Yotei brings over many of the same elements as its 2020 predecessor Ghost of Tsushima while channeling similar vibes that made the studio’s Sly Cooper and Infamous franchises so appealing. Acclaimed as Tsushima was, it could feel like it was trying too hard to look like it was successfully mimicking the Japanese films that inspired it. But Yotei continually showed Sucker Punch’s greater sense of confidence in itself to make its own spin on Japanese action stories rather than just emulating the movies that inspired it. 

That’s most apparent in its combat, which retains Tsushima’s core mechanics while carving its own distinct path. Stances are out, replaced with different weapons intended for specific enemies, like the dual katanas for spearmen and the odachi for massive brutes. The rock-paper-scissors dynamic against multiple enemies makes fights fun as Atsu’s arsenal grows to include ranged weapons and quickfire tools, and disarming enemies (or being disarmed by them) can further change things up at a moment’s notice. (Picking up fallen weapons to chuck at enemies? Never gets old.)

© Sucker Punch/PlayStation

Atsu’s most significant additions come via story or side missions that pair her with an expert in that particular armament. The melee weapons see her train with a local master who gives her a quick rundown of their base moves, followed by a chain of side quests that culminate in learning a new combat technique. While the masters don’t play any real narrative role after the initial training, their individual stories and the additional context make acquiring these weapons feel special, and some of the introductory quests have neat gimmicks, like using one side of the controller to train Atsu’s weak hand. And she can only learn new weapon skills at altars strewn around Ezo or at enemy strongholds that need clearing out.

While the combat remains strong, stealth still hasn’t risen to the occasion. Sucker Punch tries to change things up by not giving Atsu the listening ability that lets her track enemies until well into the story. Until then, she can use her spyglass to observe the area and spot points of interest. In practice, the spyglass doesn’t add anything substantial that can’t already be gleaned when the game tells her to look at her surroundings, and it’s effectively useless once her listen power eventually comes into play. It’s still satisfying to clear an area without being spotted, but going quiet doesn’t feel as strong as it could. The story scenarios around the stealth sections can be creative, but they themselves are not, and they don’t endeavor to push you to employ new tactics as you would in other stealth-focused games.

Like Tsushima before it, Ghost of Yotei wants to draw the player into its digital recreation of 1603 Ezo. Using wind and animals to naturally guide players around still works on a navigation and immersive level, and the art direction is as striking as ever. As with Tsushima, Ezo has plenty of areas that exist to let the player take in the scenery and snap photos, and the screen adding black bars during horse rides further helps with the absorption. Where Tsushima was split across three zones in a video game-y way, Ezo feels more like a real place with less defined borders. The inns and communities Atsu travels to feel shaped by the presence of the Yotei Six or the samurai clan warring against their leader, Lord Saito, who in turn reacts to Atsu’s actions throughout the story. 

Yotei doesn’t offer a fully reactive world shaped by what Atsu does, but it properly meets Atsu’s growing power. Whenever a member of the Six has fallen, her bounty increases and her wanted poster changes to make her look increasingly menacing, making it fun to overhear travelers and ronin discuss what she’s done. I once fast traveled to an inn at the start of the game, where higher-ranking samurai were demanding to know where I was; another encounter with a similar group much later on led to my defeat, only to turn out to be a kidnapping I could escape from and kill my captors. Combined with the different tactics and weapons they deploy—spoiler, it turns out guns are their friends much more than yours—victories over these growing escalations continually feel earned in missions or exploring Ezo.

Not everyone is hostile to Atsu’s presence; wives of slain samurai will commend her for bringing the Six to justice and hub areas have gift altars with notes encouraging her to continue her revenge quest. A handful of times while doing a bamboo strike minigame, a crowd would excitedly gather around me as I sliced through poles, reacting to my successful or failed cuts. There are several bounties Atsu can take on to earn some extra money and even incorporate side activities like gambling dens and her shamisen in interesting ways.

Ghost Of Yōtei 20250905110451
© Sucker Punch/PlayStation

These moments went a long way toward encouraging exploration and imbued the sequel with greater charm and personality, which many felt was lacking from Ghost of Tsushima. While it’s still generally running the playbook of somberness as Tsushima, it has less of a stick up its ass and lets itself have some fun. Enough humor is doled out without undermining the tone and several missions carry a spark that’s defined some of the studio’s best work. 

Further helping Ghost of Yotei is its cast and Atsu in particular. She feels like a character more in tune with the developer’s narrative strengths, and in turn, it leads to a compelling performance from Erika Ishii. Where Tsushima protagonist Jin Sakai came off too emotionally detached, Atsu is easier to connect with and gets plenty of moments to let her walls down as she crosses paths with several key allies in her journey. The “Wolf Pack” tab that keeps track of these supporting players is more of a lore guide than a relationship tracker, but it further helps get into Atsu’s headspace as the story progresses. 

Narratively, Ghost of Yotei contains few surprises, but it’s balanced out by how well it’s told and the performances of its cast. In the Yotei Six, Sucker Punch dips back into familiar villainous territory—the original Sly Cooper was also a revenge quest, albeit a more kid-friendly one—and paints each member with some character to be more than one note. Most of them are a sad lot in some fashion, but none of them are ever let off the hook for that night at Atsu’s home, and the gradual reveal of why they targeted her family and their relationships with one another all come together well. None of them also overstay their welcome, and Atsu is within their proximity long enough to make you understand why she and the rest of Ezo hold them in such contempt. 

Enough goodwill is built up throughout the story that it’s a shame when it can’t avoid slipping up. Yotei plays its thematic hand a bit too early, causing several beats in the back half to feel like they should go the opposite of how they normally play out in stories like these. That the game keeps such focus on Atsu’s personal journey also inevitably leaves a plot thread involving an ally samurai clan feeling somewhat abandoned. At first, Yotei takes its time dulling the shine off the warrior class as a means of addressing criticisms toward Ghost of Tsushima for being overly fawning towards them. There’s an undercurrent of class that persists throughout several story beats, giving Atsu’s interactions with samurai and the common folk a distinct edge that Jin’s story did not for most of its runtime.

While these moments of samurai slander are heavy-handed, they’re not unwelcome, and they’re eventually complicated by interesting narrative wrinkles. As such, it’s all the stranger when this samurai thread doesn’t get any closure en route to the finale, even when they’re forced into Atsu’s orbit as part of its ongoing escalation. Yotei is often enthusiastically in conversation with Tsushima, so this oversight feels like a punch pulled to avoid coming off as overly mean toward its predecessor, despite that first game laying the foundation for the sequel to even hit these criticisms at all, albeit unintentionally. 

That Ghost of Yotei can’t entirely seal the deal narratively isn’t the worst black mark against it, and where the story eventually goes lands so well this might not even matter for some. But for a game so strong in nearly every other area, it shows Sucker Punch still has areas to improve as it strives to create the perfect samurai and shinobi simulator. Not too much, though—the studio is already on the right path, as made clear by my 40-hour playthrough with one of its strongest titles to date.

Ghost of Yotei releases October 2 on PlayStation 5.

Want more io9 news? Check out when to expect the latest Marvel, Star Wars, and Star Trek releases, what’s next for the DC Universe on film and TV, and everything you need to know about the future of Doctor Who.

Source link
#Ghost #Yotei #Stronger #SelfAssured #Sequel

officially unveiled the Luna Band, a new voice-first wearable designed to help users improve their daily routines through real-time health tracking. Supported by the company’s LifeOS intelligence system, the wearable continuously monitors body signals and transforms them into personalized recommendations. Luna designed the device for people who want smarter support for productivity, recovery, and overall health. The invite-only Drop 1 is expected to begin shipping by the end of July 2026.

Luna Band: Key Highlights

Luna designed the Luna app to make health tracking simpler and more organized by consolidating several wellness features into a single platform. This app integrates features that involve stress management, nutrition, exercise, supplements, and recovery into a single application. Another customization option available to users is creating personal health modules in the app.

The application brings together aspects of stress, diet, fitness, nutritional supplements, and productivity within the app’s micro-apps. Users can also sync third-party devices and other relevant health-related data sources for a more personalized experience.

Luna Introduces Luna Band With Real-Time Health Tracking Features
	
Luna has officially unveiled the Luna Band, a new voice-first wearable designed to help users improve their daily routines through real-time health tracking. Supported by the company’s LifeOS intelligence system, the wearable continuously monitors body signals and transforms them into personalized recommendations. Luna designed the device for people who want smarter support for productivity, recovery, and overall health. The invite-only Drop 1 is expected to begin shipping by the end of July 2026.



Luna Band: Key Highlights



Luna designed the Luna app to make health tracking simpler and more organized by consolidating several wellness features into a single platform. This app integrates features that involve stress management, nutrition, exercise, supplements, and recovery into a single application. Another customization option available to users is creating personal health modules in the app.



The application brings together aspects of stress, diet, fitness, nutritional supplements, and productivity within the app’s micro-apps. Users can also sync third-party devices and other relevant health-related data sources for a more personalized experience.







The company also allows users to create their own health modules in the app rather than relying solely on prebuilt features. Alongside this, Luna highlights its voice-logging feature, which eliminates the need for manual data entry. Users can quickly record meals, workouts, and daily habits through simple voice commands, making health tracking faster.



Luna designed LifeOS as one of its main AI-powered features to simplify health tracking through personalized insights and recommendations. The system continuously studies body signals, lifestyle habits, biomarkers, and health trends to deliver a better understanding of overall wellness. Luna says LifeOS is included with the Luna Band platform.



Price and Availability



Luna has confirmed that the first release of the Luna Band, called Drop 1, will be available through an invite-only system. Users interested in the wearable can sign up through the company’s official waitlist before shipping starts later in July 2026. 

#Luna #Introduces #Luna #Band #RealTime #Health #Tracking #FeaturesLuna

The company also allows users to create their own health modules in the app rather than relying solely on prebuilt features. Alongside this, Luna highlights its voice-logging feature, which eliminates the need for manual data entry. Users can quickly record meals, workouts, and daily habits through simple voice commands, making health tracking faster.

Luna designed LifeOS as one of its main AI-powered features to simplify health tracking through personalized insights and recommendations. The system continuously studies body signals, lifestyle habits, biomarkers, and health trends to deliver a better understanding of overall wellness. Luna says LifeOS is included with the Luna Band platform.

Price and Availability

Luna has confirmed that the first release of the Luna Band, called Drop 1, will be available through an invite-only system. Users interested in the wearable can sign up through the company’s official waitlist before shipping starts later in July 2026.

#Luna #Introduces #Luna #Band #RealTime #Health #Tracking #FeaturesLuna">Luna Introduces Luna Band With Real-Time Health Tracking Features
	
Luna has officially unveiled the Luna Band, a new voice-first wearable designed to help users improve their daily routines through real-time health tracking. Supported by the company’s LifeOS intelligence system, the wearable continuously monitors body signals and transforms them into personalized recommendations. Luna designed the device for people who want smarter support for productivity, recovery, and overall health. The invite-only Drop 1 is expected to begin shipping by the end of July 2026.



Luna Band: Key Highlights



Luna designed the Luna app to make health tracking simpler and more organized by consolidating several wellness features into a single platform. This app integrates features that involve stress management, nutrition, exercise, supplements, and recovery into a single application. Another customization option available to users is creating personal health modules in the app.



The application brings together aspects of stress, diet, fitness, nutritional supplements, and productivity within the app’s micro-apps. Users can also sync third-party devices and other relevant health-related data sources for a more personalized experience.







The company also allows users to create their own health modules in the app rather than relying solely on prebuilt features. Alongside this, Luna highlights its voice-logging feature, which eliminates the need for manual data entry. Users can quickly record meals, workouts, and daily habits through simple voice commands, making health tracking faster.



Luna designed LifeOS as one of its main AI-powered features to simplify health tracking through personalized insights and recommendations. The system continuously studies body signals, lifestyle habits, biomarkers, and health trends to deliver a better understanding of overall wellness. Luna says LifeOS is included with the Luna Band platform.



Price and Availability



Luna has confirmed that the first release of the Luna Band, called Drop 1, will be available through an invite-only system. Users interested in the wearable can sign up through the company’s official waitlist before shipping starts later in July 2026. 

#Luna #Introduces #Luna #Band #RealTime #Health #Tracking #FeaturesLuna

the Luna Band, a new voice-first wearable designed to help users improve their daily routines through real-time health tracking. Supported by the company’s LifeOS intelligence system, the wearable continuously monitors body signals and transforms them into personalized recommendations. Luna designed the device for people who want smarter support for productivity, recovery, and overall health. The invite-only Drop 1 is expected to begin shipping by the end of July 2026.

Luna Band: Key Highlights

Luna designed the Luna app to make health tracking simpler and more organized by consolidating several wellness features into a single platform. This app integrates features that involve stress management, nutrition, exercise, supplements, and recovery into a single application. Another customization option available to users is creating personal health modules in the app.

The application brings together aspects of stress, diet, fitness, nutritional supplements, and productivity within the app’s micro-apps. Users can also sync third-party devices and other relevant health-related data sources for a more personalized experience.

Luna Introduces Luna Band With Real-Time Health Tracking Features
	
Luna has officially unveiled the Luna Band, a new voice-first wearable designed to help users improve their daily routines through real-time health tracking. Supported by the company’s LifeOS intelligence system, the wearable continuously monitors body signals and transforms them into personalized recommendations. Luna designed the device for people who want smarter support for productivity, recovery, and overall health. The invite-only Drop 1 is expected to begin shipping by the end of July 2026.



Luna Band: Key Highlights



Luna designed the Luna app to make health tracking simpler and more organized by consolidating several wellness features into a single platform. This app integrates features that involve stress management, nutrition, exercise, supplements, and recovery into a single application. Another customization option available to users is creating personal health modules in the app.



The application brings together aspects of stress, diet, fitness, nutritional supplements, and productivity within the app’s micro-apps. Users can also sync third-party devices and other relevant health-related data sources for a more personalized experience.







The company also allows users to create their own health modules in the app rather than relying solely on prebuilt features. Alongside this, Luna highlights its voice-logging feature, which eliminates the need for manual data entry. Users can quickly record meals, workouts, and daily habits through simple voice commands, making health tracking faster.



Luna designed LifeOS as one of its main AI-powered features to simplify health tracking through personalized insights and recommendations. The system continuously studies body signals, lifestyle habits, biomarkers, and health trends to deliver a better understanding of overall wellness. Luna says LifeOS is included with the Luna Band platform.



Price and Availability



Luna has confirmed that the first release of the Luna Band, called Drop 1, will be available through an invite-only system. Users interested in the wearable can sign up through the company’s official waitlist before shipping starts later in July 2026. 

#Luna #Introduces #Luna #Band #RealTime #Health #Tracking #FeaturesLuna

The company also allows users to create their own health modules in the app rather than relying solely on prebuilt features. Alongside this, Luna highlights its voice-logging feature, which eliminates the need for manual data entry. Users can quickly record meals, workouts, and daily habits through simple voice commands, making health tracking faster.

Luna designed LifeOS as one of its main AI-powered features to simplify health tracking through personalized insights and recommendations. The system continuously studies body signals, lifestyle habits, biomarkers, and health trends to deliver a better understanding of overall wellness. Luna says LifeOS is included with the Luna Band platform.

Price and Availability

Luna has confirmed that the first release of the Luna Band, called Drop 1, will be available through an invite-only system. Users interested in the wearable can sign up through the company’s official waitlist before shipping starts later in July 2026.

#Luna #Introduces #Luna #Band #RealTime #Health #Tracking #FeaturesLuna">Luna Introduces Luna Band With Real-Time Health Tracking Features

Luna has officially unveiled the Luna Band, a new voice-first wearable designed to help users improve their daily routines through real-time health tracking. Supported by the company’s LifeOS intelligence system, the wearable continuously monitors body signals and transforms them into personalized recommendations. Luna designed the device for people who want smarter support for productivity, recovery, and overall health. The invite-only Drop 1 is expected to begin shipping by the end of July 2026.

Luna Band: Key Highlights

Luna designed the Luna app to make health tracking simpler and more organized by consolidating several wellness features into a single platform. This app integrates features that involve stress management, nutrition, exercise, supplements, and recovery into a single application. Another customization option available to users is creating personal health modules in the app.

The application brings together aspects of stress, diet, fitness, nutritional supplements, and productivity within the app’s micro-apps. Users can also sync third-party devices and other relevant health-related data sources for a more personalized experience.

Luna Introduces Luna Band With Real-Time Health Tracking Features
	
Luna has officially unveiled the Luna Band, a new voice-first wearable designed to help users improve their daily routines through real-time health tracking. Supported by the company’s LifeOS intelligence system, the wearable continuously monitors body signals and transforms them into personalized recommendations. Luna designed the device for people who want smarter support for productivity, recovery, and overall health. The invite-only Drop 1 is expected to begin shipping by the end of July 2026.



Luna Band: Key Highlights



Luna designed the Luna app to make health tracking simpler and more organized by consolidating several wellness features into a single platform. This app integrates features that involve stress management, nutrition, exercise, supplements, and recovery into a single application. Another customization option available to users is creating personal health modules in the app.



The application brings together aspects of stress, diet, fitness, nutritional supplements, and productivity within the app’s micro-apps. Users can also sync third-party devices and other relevant health-related data sources for a more personalized experience.







The company also allows users to create their own health modules in the app rather than relying solely on prebuilt features. Alongside this, Luna highlights its voice-logging feature, which eliminates the need for manual data entry. Users can quickly record meals, workouts, and daily habits through simple voice commands, making health tracking faster.



Luna designed LifeOS as one of its main AI-powered features to simplify health tracking through personalized insights and recommendations. The system continuously studies body signals, lifestyle habits, biomarkers, and health trends to deliver a better understanding of overall wellness. Luna says LifeOS is included with the Luna Band platform.



Price and Availability



Luna has confirmed that the first release of the Luna Band, called Drop 1, will be available through an invite-only system. Users interested in the wearable can sign up through the company’s official waitlist before shipping starts later in July 2026. 

#Luna #Introduces #Luna #Band #RealTime #Health #Tracking #FeaturesLuna

The company also allows users to create their own health modules in the app rather than relying solely on prebuilt features. Alongside this, Luna highlights its voice-logging feature, which eliminates the need for manual data entry. Users can quickly record meals, workouts, and daily habits through simple voice commands, making health tracking faster.

Luna designed LifeOS as one of its main AI-powered features to simplify health tracking through personalized insights and recommendations. The system continuously studies body signals, lifestyle habits, biomarkers, and health trends to deliver a better understanding of overall wellness. Luna says LifeOS is included with the Luna Band platform.

Price and Availability

Luna has confirmed that the first release of the Luna Band, called Drop 1, will be available through an invite-only system. Users interested in the wearable can sign up through the company’s official waitlist before shipping starts later in July 2026.

#Luna #Introduces #Luna #Band #RealTime #Health #Tracking #FeaturesLuna
suggested that GLP-1s can tamp down people’s unhealthy urges for alcohol, cocaine, and even vices like gambling. And earlier this month, researchers in Denmark published data from the first double-blinded, randomized, and placebo-controlled trial of semaglutide for alcohol use disorder in The Lancet. Over a 26-week period, the study found that people on semaglutide consumed less alcohol than those given a placebo and experienced noticeably fewer heavy drinking days when they did drink.

Can Ozempic Treat Alcoholism? Here’s What You Should Know
                Semaglutide (the active ingredient in Ozempic and Wegovy) and other GLP-1 medications have rapidly become some of the most popular drugs in the world. Originally developed for type 2 diabetes, GLP-1s are now better known for treating obesity. In the near future, though, these drugs could have yet another vital use as treatments for alcohol addiction and other substance use disorders. Over the past few years, a growing base of evidence has suggested that GLP-1s can tamp down people’s unhealthy urges for alcohol, cocaine, and even vices like gambling. And earlier this month, researchers in Denmark published data from the first double-blinded, randomized, and placebo-controlled trial of semaglutide for alcohol use disorder in The Lancet. Over a 26-week period, the study found that people on semaglutide consumed less alcohol than those given a placebo and experienced noticeably fewer heavy drinking days when they did drink. © siamionau pavel via Shutterstock There are other similar studies underway, including in the United States. Some are testing semaglutide for other kinds of substance use disorder, like opioids. Others are testing newer drugs like tirzepatide (a dual agonist that pairs GLP-1 with the hunger-related hormone GIP).

 I reached out to an outside expert, Asim Shah, a professor and executive vice chair of psychiatry and behavioral sciences at Baylor College of Medicine, to talk about the emerging science surrounding GLP-1s and addiction treatment. We discussed the leading theory behind why GLP-1s can reduce addiction, his opinion of the recent Lancet trial, and what it will take for these drugs to be widely adopted as treatments for substance use disorders. The following has been lightly edited for clarity and grammar.

 Ed Cara, Gizmodo: Do we have any sort of sense yet as to how or why GLP-1s seem to be working well against substance use disorders? Asim Shah: So the craving, or pleasure, center of the brain is related to dopamine, which is a brain neurotransmitter. Whenever you crave something and you eat it or you take it, that gives you pleasure. That is the dopamine functioning in the brain. And all of this is related to the same thing, whether it’s a craving for food, craving for smoking, craving for alcohol, any drug. That’s the neurobiological mechanism of craving and pleasure, and it’s all the same mechanism.

 © Mohammed_Al_Ali via Shutterstock And incidentally, we found out that the people who were losing weight on these GLP-1s, they often also stopped smoking cigarettes and their addiction got better with alcohol. It was an incidental finding, but it’s something people are now trying to study more closely. Gizmodo: Speaking of studies, what do you make of the newest trial published in The Lancet this month? Shah: So this was a 26 week study, which had about 100 patients, half and half men and women both. In our world, 100 patients is a medium sized study; a larger one might usually have 300, 400, 600 patients. So this is a medium sized study, which is decent. It’s not bad. And in my opinion, it was done pretty well, not a lot of bias in the study that I saw.

 Now, of course, this is not a definitive study. And you need to follow up with these patients after the weeks of study. We call these start-up studies, and they are what we base future, longer and bigger studies on. So it’s a good base, and there are other studies on the way. Gizmodo: Broadly speaking, what are the questions that these longer and larger studies need to try answering? Shah: So there are a couple of things. These are different substances that people are looking at; one is alcohol, one smoking, the other is opiates. So the next studies we should be doing is to see whether GLP-1s like semaglutide can limit more than one of these addictions. Because the mechanism is the same mechanism for all the cravings and the addictions. So can it reduce all of these or just one if somebody is taking it?

 © Sebastien Bozon/AFP via Getty If we do keep seeing an effect here, it’s also important to know how quickly this happens and whether it can be sustained after you stop using a GLP-1. That’s why we have to follow people after these sorts of trials, to see if the effect can last after they stop taking the medication or if it requires people needing to stay on the drug for the effect. Gizmodo: These sort of studies are happening. But what should be the current takeaway for people with these addictions and their doctor? Is this something that could be used in the real world right now? Shah: Because they’re not approved right now, the takeaway should be that if you already have a current indication to take a GLP-1 which is for diabetes or obesity, certainly take it. If you also get an added advantage of stopping your smoking or alcohol use disorder, that is well and good because we don’t have approval for these disorders currently.

 So in other words, if somebody comes to us and says, “Hey, I want to start these medicines for smoking cessation or alcohol use disorder,” we may not be able to prescribe it because there’s no approval. But they can be part of a study which is going on in some centers for those disorders. And if somebody already is using them for diabetes or so, and in addition, they get a benefit for alcoholism, that’s great, too.      #Ozempic #Treat #Alcoholism #Heresaddiction,Alcoholism,GLP-1s,Ozempic,Q&As
© siamionau pavel via Shutterstock

There are other similar studies underway, including in the United States. Some are testing semaglutide for other kinds of substance use disorder, like opioids. Others are testing newer drugs like tirzepatide (a dual agonist that pairs GLP-1 with the hunger-related hormone GIP).

I reached out to an outside expert, Asim Shah, a professor and executive vice chair of psychiatry and behavioral sciences at Baylor College of Medicine, to talk about the emerging science surrounding GLP-1s and addiction treatment. We discussed the leading theory behind why GLP-1s can reduce addiction, his opinion of the recent Lancet trial, and what it will take for these drugs to be widely adopted as treatments for substance use disorders. The following has been lightly edited for clarity and grammar.

Ed Cara, Gizmodo: Do we have any sort of sense yet as to how or why GLP-1s seem to be working well against substance use disorders?

Asim Shah: So the craving, or pleasure, center of the brain is related to dopamine, which is a brain neurotransmitter. Whenever you crave something and you eat it or you take it, that gives you pleasure. That is the dopamine functioning in the brain. And all of this is related to the same thing, whether it’s a craving for food, craving for smoking, craving for alcohol, any drug. That’s the neurobiological mechanism of craving and pleasure, and it’s all the same mechanism.

The obesity medication Saxenda, made with liraglutide
© Mohammed_Al_Ali via Shutterstock

And incidentally, we found out that the people who were losing weight on these GLP-1s, they often also stopped smoking cigarettes and their addiction got better with alcohol. It was an incidental finding, but it’s something people are now trying to study more closely.

Gizmodo: Speaking of studies, what do you make of the newest trial published in The Lancet this month?

Shah: So this was a 26 week study, which had about 100 patients, half and half men and women both. In our world, 100 patients is a medium sized study; a larger one might usually have 300, 400, 600 patients. So this is a medium sized study, which is decent. It’s not bad. And in my opinion, it was done pretty well, not a lot of bias in the study that I saw.

Now, of course, this is not a definitive study. And you need to follow up with these patients after the weeks of study. We call these start-up studies, and they are what we base future, longer and bigger studies on. So it’s a good base, and there are other studies on the way.

Gizmodo: Broadly speaking, what are the questions that these longer and larger studies need to try answering?

Shah: So there are a couple of things.

These are different substances that people are looking at; one is alcohol, one smoking, the other is opiates. So the next studies we should be doing is to see whether GLP-1s like semaglutide can limit more than one of these addictions. Because the mechanism is the same mechanism for all the cravings and the addictions. So can it reduce all of these or just one if somebody is taking it?

Boxes of the GLP-1 medication Ozempic
© Sebastien Bozon/AFP via Getty

If we do keep seeing an effect here, it’s also important to know how quickly this happens and whether it can be sustained after you stop using a GLP-1. That’s why we have to follow people after these sorts of trials, to see if the effect can last after they stop taking the medication or if it requires people needing to stay on the drug for the effect.

Gizmodo: These sort of studies are happening. But what should be the current takeaway for people with these addictions and their doctor? Is this something that could be used in the real world right now?

Shah: Because they’re not approved right now, the takeaway should be that if you already have a current indication to take a GLP-1 which is for diabetes or obesity, certainly take it. If you also get an added advantage of stopping your smoking or alcohol use disorder, that is well and good because we don’t have approval for these disorders currently.

So in other words, if somebody comes to us and says, “Hey, I want to start these medicines for smoking cessation or alcohol use disorder,” we may not be able to prescribe it because there’s no approval. But they can be part of a study which is going on in some centers for those disorders. And if somebody already is using them for diabetes or so, and in addition, they get a benefit for alcoholism, that’s great, too.

#Ozempic #Treat #Alcoholism #Heresaddiction,Alcoholism,GLP-1s,Ozempic,Q&As">Can Ozempic Treat Alcoholism? Here’s What You Should Know
                Semaglutide (the active ingredient in Ozempic and Wegovy) and other GLP-1 medications have rapidly become some of the most popular drugs in the world. Originally developed for type 2 diabetes, GLP-1s are now better known for treating obesity. In the near future, though, these drugs could have yet another vital use as treatments for alcohol addiction and other substance use disorders. Over the past few years, a growing base of evidence has suggested that GLP-1s can tamp down people’s unhealthy urges for alcohol, cocaine, and even vices like gambling. And earlier this month, researchers in Denmark published data from the first double-blinded, randomized, and placebo-controlled trial of semaglutide for alcohol use disorder in The Lancet. Over a 26-week period, the study found that people on semaglutide consumed less alcohol than those given a placebo and experienced noticeably fewer heavy drinking days when they did drink. © siamionau pavel via Shutterstock There are other similar studies underway, including in the United States. Some are testing semaglutide for other kinds of substance use disorder, like opioids. Others are testing newer drugs like tirzepatide (a dual agonist that pairs GLP-1 with the hunger-related hormone GIP).

 I reached out to an outside expert, Asim Shah, a professor and executive vice chair of psychiatry and behavioral sciences at Baylor College of Medicine, to talk about the emerging science surrounding GLP-1s and addiction treatment. We discussed the leading theory behind why GLP-1s can reduce addiction, his opinion of the recent Lancet trial, and what it will take for these drugs to be widely adopted as treatments for substance use disorders. The following has been lightly edited for clarity and grammar.

 Ed Cara, Gizmodo: Do we have any sort of sense yet as to how or why GLP-1s seem to be working well against substance use disorders? Asim Shah: So the craving, or pleasure, center of the brain is related to dopamine, which is a brain neurotransmitter. Whenever you crave something and you eat it or you take it, that gives you pleasure. That is the dopamine functioning in the brain. And all of this is related to the same thing, whether it’s a craving for food, craving for smoking, craving for alcohol, any drug. That’s the neurobiological mechanism of craving and pleasure, and it’s all the same mechanism.

 © Mohammed_Al_Ali via Shutterstock And incidentally, we found out that the people who were losing weight on these GLP-1s, they often also stopped smoking cigarettes and their addiction got better with alcohol. It was an incidental finding, but it’s something people are now trying to study more closely. Gizmodo: Speaking of studies, what do you make of the newest trial published in The Lancet this month? Shah: So this was a 26 week study, which had about 100 patients, half and half men and women both. In our world, 100 patients is a medium sized study; a larger one might usually have 300, 400, 600 patients. So this is a medium sized study, which is decent. It’s not bad. And in my opinion, it was done pretty well, not a lot of bias in the study that I saw.

 Now, of course, this is not a definitive study. And you need to follow up with these patients after the weeks of study. We call these start-up studies, and they are what we base future, longer and bigger studies on. So it’s a good base, and there are other studies on the way. Gizmodo: Broadly speaking, what are the questions that these longer and larger studies need to try answering? Shah: So there are a couple of things. These are different substances that people are looking at; one is alcohol, one smoking, the other is opiates. So the next studies we should be doing is to see whether GLP-1s like semaglutide can limit more than one of these addictions. Because the mechanism is the same mechanism for all the cravings and the addictions. So can it reduce all of these or just one if somebody is taking it?

 © Sebastien Bozon/AFP via Getty If we do keep seeing an effect here, it’s also important to know how quickly this happens and whether it can be sustained after you stop using a GLP-1. That’s why we have to follow people after these sorts of trials, to see if the effect can last after they stop taking the medication or if it requires people needing to stay on the drug for the effect. Gizmodo: These sort of studies are happening. But what should be the current takeaway for people with these addictions and their doctor? Is this something that could be used in the real world right now? Shah: Because they’re not approved right now, the takeaway should be that if you already have a current indication to take a GLP-1 which is for diabetes or obesity, certainly take it. If you also get an added advantage of stopping your smoking or alcohol use disorder, that is well and good because we don’t have approval for these disorders currently.

 So in other words, if somebody comes to us and says, “Hey, I want to start these medicines for smoking cessation or alcohol use disorder,” we may not be able to prescribe it because there’s no approval. But they can be part of a study which is going on in some centers for those disorders. And if somebody already is using them for diabetes or so, and in addition, they get a benefit for alcoholism, that’s great, too.      #Ozempic #Treat #Alcoholism #Heresaddiction,Alcoholism,GLP-1s,Ozempic,Q&As

that GLP-1s can tamp down people’s unhealthy urges for alcohol, cocaine, and even vices like gambling. And earlier this month, researchers in Denmark published data from the first double-blinded, randomized, and placebo-controlled trial of semaglutide for alcohol use disorder in The Lancet. Over a 26-week period, the study found that people on semaglutide consumed less alcohol than those given a placebo and experienced noticeably fewer heavy drinking days when they did drink.

Can Ozempic Treat Alcoholism? Here’s What You Should Know
                Semaglutide (the active ingredient in Ozempic and Wegovy) and other GLP-1 medications have rapidly become some of the most popular drugs in the world. Originally developed for type 2 diabetes, GLP-1s are now better known for treating obesity. In the near future, though, these drugs could have yet another vital use as treatments for alcohol addiction and other substance use disorders. Over the past few years, a growing base of evidence has suggested that GLP-1s can tamp down people’s unhealthy urges for alcohol, cocaine, and even vices like gambling. And earlier this month, researchers in Denmark published data from the first double-blinded, randomized, and placebo-controlled trial of semaglutide for alcohol use disorder in The Lancet. Over a 26-week period, the study found that people on semaglutide consumed less alcohol than those given a placebo and experienced noticeably fewer heavy drinking days when they did drink. © siamionau pavel via Shutterstock There are other similar studies underway, including in the United States. Some are testing semaglutide for other kinds of substance use disorder, like opioids. Others are testing newer drugs like tirzepatide (a dual agonist that pairs GLP-1 with the hunger-related hormone GIP).

 I reached out to an outside expert, Asim Shah, a professor and executive vice chair of psychiatry and behavioral sciences at Baylor College of Medicine, to talk about the emerging science surrounding GLP-1s and addiction treatment. We discussed the leading theory behind why GLP-1s can reduce addiction, his opinion of the recent Lancet trial, and what it will take for these drugs to be widely adopted as treatments for substance use disorders. The following has been lightly edited for clarity and grammar.

 Ed Cara, Gizmodo: Do we have any sort of sense yet as to how or why GLP-1s seem to be working well against substance use disorders? Asim Shah: So the craving, or pleasure, center of the brain is related to dopamine, which is a brain neurotransmitter. Whenever you crave something and you eat it or you take it, that gives you pleasure. That is the dopamine functioning in the brain. And all of this is related to the same thing, whether it’s a craving for food, craving for smoking, craving for alcohol, any drug. That’s the neurobiological mechanism of craving and pleasure, and it’s all the same mechanism.

 © Mohammed_Al_Ali via Shutterstock And incidentally, we found out that the people who were losing weight on these GLP-1s, they often also stopped smoking cigarettes and their addiction got better with alcohol. It was an incidental finding, but it’s something people are now trying to study more closely. Gizmodo: Speaking of studies, what do you make of the newest trial published in The Lancet this month? Shah: So this was a 26 week study, which had about 100 patients, half and half men and women both. In our world, 100 patients is a medium sized study; a larger one might usually have 300, 400, 600 patients. So this is a medium sized study, which is decent. It’s not bad. And in my opinion, it was done pretty well, not a lot of bias in the study that I saw.

 Now, of course, this is not a definitive study. And you need to follow up with these patients after the weeks of study. We call these start-up studies, and they are what we base future, longer and bigger studies on. So it’s a good base, and there are other studies on the way. Gizmodo: Broadly speaking, what are the questions that these longer and larger studies need to try answering? Shah: So there are a couple of things. These are different substances that people are looking at; one is alcohol, one smoking, the other is opiates. So the next studies we should be doing is to see whether GLP-1s like semaglutide can limit more than one of these addictions. Because the mechanism is the same mechanism for all the cravings and the addictions. So can it reduce all of these or just one if somebody is taking it?

 © Sebastien Bozon/AFP via Getty If we do keep seeing an effect here, it’s also important to know how quickly this happens and whether it can be sustained after you stop using a GLP-1. That’s why we have to follow people after these sorts of trials, to see if the effect can last after they stop taking the medication or if it requires people needing to stay on the drug for the effect. Gizmodo: These sort of studies are happening. But what should be the current takeaway for people with these addictions and their doctor? Is this something that could be used in the real world right now? Shah: Because they’re not approved right now, the takeaway should be that if you already have a current indication to take a GLP-1 which is for diabetes or obesity, certainly take it. If you also get an added advantage of stopping your smoking or alcohol use disorder, that is well and good because we don’t have approval for these disorders currently.

 So in other words, if somebody comes to us and says, “Hey, I want to start these medicines for smoking cessation or alcohol use disorder,” we may not be able to prescribe it because there’s no approval. But they can be part of a study which is going on in some centers for those disorders. And if somebody already is using them for diabetes or so, and in addition, they get a benefit for alcoholism, that’s great, too.      #Ozempic #Treat #Alcoholism #Heresaddiction,Alcoholism,GLP-1s,Ozempic,Q&As
© siamionau pavel via Shutterstock

There are other similar studies underway, including in the United States. Some are testing semaglutide for other kinds of substance use disorder, like opioids. Others are testing newer drugs like tirzepatide (a dual agonist that pairs GLP-1 with the hunger-related hormone GIP).

I reached out to an outside expert, Asim Shah, a professor and executive vice chair of psychiatry and behavioral sciences at Baylor College of Medicine, to talk about the emerging science surrounding GLP-1s and addiction treatment. We discussed the leading theory behind why GLP-1s can reduce addiction, his opinion of the recent Lancet trial, and what it will take for these drugs to be widely adopted as treatments for substance use disorders. The following has been lightly edited for clarity and grammar.

Ed Cara, Gizmodo: Do we have any sort of sense yet as to how or why GLP-1s seem to be working well against substance use disorders?

Asim Shah: So the craving, or pleasure, center of the brain is related to dopamine, which is a brain neurotransmitter. Whenever you crave something and you eat it or you take it, that gives you pleasure. That is the dopamine functioning in the brain. And all of this is related to the same thing, whether it’s a craving for food, craving for smoking, craving for alcohol, any drug. That’s the neurobiological mechanism of craving and pleasure, and it’s all the same mechanism.

The obesity medication Saxenda, made with liraglutide
© Mohammed_Al_Ali via Shutterstock

And incidentally, we found out that the people who were losing weight on these GLP-1s, they often also stopped smoking cigarettes and their addiction got better with alcohol. It was an incidental finding, but it’s something people are now trying to study more closely.

Gizmodo: Speaking of studies, what do you make of the newest trial published in The Lancet this month?

Shah: So this was a 26 week study, which had about 100 patients, half and half men and women both. In our world, 100 patients is a medium sized study; a larger one might usually have 300, 400, 600 patients. So this is a medium sized study, which is decent. It’s not bad. And in my opinion, it was done pretty well, not a lot of bias in the study that I saw.

Now, of course, this is not a definitive study. And you need to follow up with these patients after the weeks of study. We call these start-up studies, and they are what we base future, longer and bigger studies on. So it’s a good base, and there are other studies on the way.

Gizmodo: Broadly speaking, what are the questions that these longer and larger studies need to try answering?

Shah: So there are a couple of things.

These are different substances that people are looking at; one is alcohol, one smoking, the other is opiates. So the next studies we should be doing is to see whether GLP-1s like semaglutide can limit more than one of these addictions. Because the mechanism is the same mechanism for all the cravings and the addictions. So can it reduce all of these or just one if somebody is taking it?

Boxes of the GLP-1 medication Ozempic
© Sebastien Bozon/AFP via Getty

If we do keep seeing an effect here, it’s also important to know how quickly this happens and whether it can be sustained after you stop using a GLP-1. That’s why we have to follow people after these sorts of trials, to see if the effect can last after they stop taking the medication or if it requires people needing to stay on the drug for the effect.

Gizmodo: These sort of studies are happening. But what should be the current takeaway for people with these addictions and their doctor? Is this something that could be used in the real world right now?

Shah: Because they’re not approved right now, the takeaway should be that if you already have a current indication to take a GLP-1 which is for diabetes or obesity, certainly take it. If you also get an added advantage of stopping your smoking or alcohol use disorder, that is well and good because we don’t have approval for these disorders currently.

So in other words, if somebody comes to us and says, “Hey, I want to start these medicines for smoking cessation or alcohol use disorder,” we may not be able to prescribe it because there’s no approval. But they can be part of a study which is going on in some centers for those disorders. And if somebody already is using them for diabetes or so, and in addition, they get a benefit for alcoholism, that’s great, too.

#Ozempic #Treat #Alcoholism #Heresaddiction,Alcoholism,GLP-1s,Ozempic,Q&As">Can Ozempic Treat Alcoholism? Here’s What You Should Know

Semaglutide (the active ingredient in Ozempic and Wegovy) and other GLP-1 medications have rapidly become some of the most popular drugs in the world. Originally developed for type 2 diabetes, GLP-1s are now better known for treating obesity. In the near future, though, these drugs could have yet another vital use as treatments for alcohol addiction and other substance use disorders.

Over the past few years, a growing base of evidence has suggested that GLP-1s can tamp down people’s unhealthy urges for alcohol, cocaine, and even vices like gambling. And earlier this month, researchers in Denmark published data from the first double-blinded, randomized, and placebo-controlled trial of semaglutide for alcohol use disorder in The Lancet. Over a 26-week period, the study found that people on semaglutide consumed less alcohol than those given a placebo and experienced noticeably fewer heavy drinking days when they did drink.

Can Ozempic Treat Alcoholism? Here’s What You Should Know
                Semaglutide (the active ingredient in Ozempic and Wegovy) and other GLP-1 medications have rapidly become some of the most popular drugs in the world. Originally developed for type 2 diabetes, GLP-1s are now better known for treating obesity. In the near future, though, these drugs could have yet another vital use as treatments for alcohol addiction and other substance use disorders. Over the past few years, a growing base of evidence has suggested that GLP-1s can tamp down people’s unhealthy urges for alcohol, cocaine, and even vices like gambling. And earlier this month, researchers in Denmark published data from the first double-blinded, randomized, and placebo-controlled trial of semaglutide for alcohol use disorder in The Lancet. Over a 26-week period, the study found that people on semaglutide consumed less alcohol than those given a placebo and experienced noticeably fewer heavy drinking days when they did drink. © siamionau pavel via Shutterstock There are other similar studies underway, including in the United States. Some are testing semaglutide for other kinds of substance use disorder, like opioids. Others are testing newer drugs like tirzepatide (a dual agonist that pairs GLP-1 with the hunger-related hormone GIP).

 I reached out to an outside expert, Asim Shah, a professor and executive vice chair of psychiatry and behavioral sciences at Baylor College of Medicine, to talk about the emerging science surrounding GLP-1s and addiction treatment. We discussed the leading theory behind why GLP-1s can reduce addiction, his opinion of the recent Lancet trial, and what it will take for these drugs to be widely adopted as treatments for substance use disorders. The following has been lightly edited for clarity and grammar.

 Ed Cara, Gizmodo: Do we have any sort of sense yet as to how or why GLP-1s seem to be working well against substance use disorders? Asim Shah: So the craving, or pleasure, center of the brain is related to dopamine, which is a brain neurotransmitter. Whenever you crave something and you eat it or you take it, that gives you pleasure. That is the dopamine functioning in the brain. And all of this is related to the same thing, whether it’s a craving for food, craving for smoking, craving for alcohol, any drug. That’s the neurobiological mechanism of craving and pleasure, and it’s all the same mechanism.

 © Mohammed_Al_Ali via Shutterstock And incidentally, we found out that the people who were losing weight on these GLP-1s, they often also stopped smoking cigarettes and their addiction got better with alcohol. It was an incidental finding, but it’s something people are now trying to study more closely. Gizmodo: Speaking of studies, what do you make of the newest trial published in The Lancet this month? Shah: So this was a 26 week study, which had about 100 patients, half and half men and women both. In our world, 100 patients is a medium sized study; a larger one might usually have 300, 400, 600 patients. So this is a medium sized study, which is decent. It’s not bad. And in my opinion, it was done pretty well, not a lot of bias in the study that I saw.

 Now, of course, this is not a definitive study. And you need to follow up with these patients after the weeks of study. We call these start-up studies, and they are what we base future, longer and bigger studies on. So it’s a good base, and there are other studies on the way. Gizmodo: Broadly speaking, what are the questions that these longer and larger studies need to try answering? Shah: So there are a couple of things. These are different substances that people are looking at; one is alcohol, one smoking, the other is opiates. So the next studies we should be doing is to see whether GLP-1s like semaglutide can limit more than one of these addictions. Because the mechanism is the same mechanism for all the cravings and the addictions. So can it reduce all of these or just one if somebody is taking it?

 © Sebastien Bozon/AFP via Getty If we do keep seeing an effect here, it’s also important to know how quickly this happens and whether it can be sustained after you stop using a GLP-1. That’s why we have to follow people after these sorts of trials, to see if the effect can last after they stop taking the medication or if it requires people needing to stay on the drug for the effect. Gizmodo: These sort of studies are happening. But what should be the current takeaway for people with these addictions and their doctor? Is this something that could be used in the real world right now? Shah: Because they’re not approved right now, the takeaway should be that if you already have a current indication to take a GLP-1 which is for diabetes or obesity, certainly take it. If you also get an added advantage of stopping your smoking or alcohol use disorder, that is well and good because we don’t have approval for these disorders currently.

 So in other words, if somebody comes to us and says, “Hey, I want to start these medicines for smoking cessation or alcohol use disorder,” we may not be able to prescribe it because there’s no approval. But they can be part of a study which is going on in some centers for those disorders. And if somebody already is using them for diabetes or so, and in addition, they get a benefit for alcoholism, that’s great, too.      #Ozempic #Treat #Alcoholism #Heresaddiction,Alcoholism,GLP-1s,Ozempic,Q&As
© siamionau pavel via Shutterstock

There are other similar studies underway, including in the United States. Some are testing semaglutide for other kinds of substance use disorder, like opioids. Others are testing newer drugs like tirzepatide (a dual agonist that pairs GLP-1 with the hunger-related hormone GIP).

I reached out to an outside expert, Asim Shah, a professor and executive vice chair of psychiatry and behavioral sciences at Baylor College of Medicine, to talk about the emerging science surrounding GLP-1s and addiction treatment. We discussed the leading theory behind why GLP-1s can reduce addiction, his opinion of the recent Lancet trial, and what it will take for these drugs to be widely adopted as treatments for substance use disorders. The following has been lightly edited for clarity and grammar.

Ed Cara, Gizmodo: Do we have any sort of sense yet as to how or why GLP-1s seem to be working well against substance use disorders?

Asim Shah: So the craving, or pleasure, center of the brain is related to dopamine, which is a brain neurotransmitter. Whenever you crave something and you eat it or you take it, that gives you pleasure. That is the dopamine functioning in the brain. And all of this is related to the same thing, whether it’s a craving for food, craving for smoking, craving for alcohol, any drug. That’s the neurobiological mechanism of craving and pleasure, and it’s all the same mechanism.

The obesity medication Saxenda, made with liraglutide
© Mohammed_Al_Ali via Shutterstock

And incidentally, we found out that the people who were losing weight on these GLP-1s, they often also stopped smoking cigarettes and their addiction got better with alcohol. It was an incidental finding, but it’s something people are now trying to study more closely.

Gizmodo: Speaking of studies, what do you make of the newest trial published in The Lancet this month?

Shah: So this was a 26 week study, which had about 100 patients, half and half men and women both. In our world, 100 patients is a medium sized study; a larger one might usually have 300, 400, 600 patients. So this is a medium sized study, which is decent. It’s not bad. And in my opinion, it was done pretty well, not a lot of bias in the study that I saw.

Now, of course, this is not a definitive study. And you need to follow up with these patients after the weeks of study. We call these start-up studies, and they are what we base future, longer and bigger studies on. So it’s a good base, and there are other studies on the way.

Gizmodo: Broadly speaking, what are the questions that these longer and larger studies need to try answering?

Shah: So there are a couple of things.

These are different substances that people are looking at; one is alcohol, one smoking, the other is opiates. So the next studies we should be doing is to see whether GLP-1s like semaglutide can limit more than one of these addictions. Because the mechanism is the same mechanism for all the cravings and the addictions. So can it reduce all of these or just one if somebody is taking it?

Boxes of the GLP-1 medication Ozempic
© Sebastien Bozon/AFP via Getty

If we do keep seeing an effect here, it’s also important to know how quickly this happens and whether it can be sustained after you stop using a GLP-1. That’s why we have to follow people after these sorts of trials, to see if the effect can last after they stop taking the medication or if it requires people needing to stay on the drug for the effect.

Gizmodo: These sort of studies are happening. But what should be the current takeaway for people with these addictions and their doctor? Is this something that could be used in the real world right now?

Shah: Because they’re not approved right now, the takeaway should be that if you already have a current indication to take a GLP-1 which is for diabetes or obesity, certainly take it. If you also get an added advantage of stopping your smoking or alcohol use disorder, that is well and good because we don’t have approval for these disorders currently.

So in other words, if somebody comes to us and says, “Hey, I want to start these medicines for smoking cessation or alcohol use disorder,” we may not be able to prescribe it because there’s no approval. But they can be part of a study which is going on in some centers for those disorders. And if somebody already is using them for diabetes or so, and in addition, they get a benefit for alcoholism, that’s great, too.

#Ozempic #Treat #Alcoholism #Heresaddiction,Alcoholism,GLP-1s,Ozempic,Q&As

Post Comment